CYDUCT Welcomes the Shift Toward Precision Molecular Testing as Demand for Personalized Health Insights Accelerates

Recent regulatory and commercial milestones demonstrate that molecular detection technologies are moving into the mainstream of preventive healthcare.

CYduct Diagnostics, Inc. (OTCMKTS:CYDX)

WESTPORT, CT, UNITED STATES, August 10, 2026 /EINPresswire.com/ -- Cyduct Diagnostics, Inc. (OTCPK: CYDX) (“Cyduct” or the “Company”), a women’s health company developing technologies to support earlier detection and more precise breast health management, today welcomed the accelerating shift toward precision testing and personalized molecular insights across cancer screening and early detection.

Cyduct Diagnostics Inc. believes the healthcare market is entering a consequential new phase, one in which molecular information increasingly complements established screening practices, provides more individualized health insights, and helps identify disease-related biological changes earlier. The Company is encouraged by the momentum building around precision molecular testing and the strong demand for more personalized health information. Its proteomic breast health platform is being developed at a time when scientific innovation is advancing rapidly and the regulatory and clinical pathways needed to evaluate these technologies are beginning to evolve.

Recent approvals of molecular screening technologies demonstrate that these approaches can move into mainstream medicine when supported by rigorous clinical evidence, a clearly defined intended use, and integration with established standards of care. As leading healthcare companies expand their portfolios to include multiple screening modalities, the Company believes precision testing is becoming an increasingly important part of the future of preventive medicine.

“This is an important signal for the entire precision-testing sector,” said Dom Gatto, Chief Executive Officer of Cyduct Diagnostics. “No single technology or screening method will meet the needs of every patient. The future is not about one test replacing every other test. It is about creating an integrated model in which imaging, molecular testing, risk assessment, and clinical follow-up work together to deliver more personalized care.” Cyduct’s long-term objective is to help bring precision medicine to the global breast health market and move the search for meaningful biological changes closer to the earliest stages of the disease process. “Our destination is clear,” Gatto concluded. “We intend to advance breast health assessment closer to the ducts, where most breast cancers begin, and provide women and their healthcare professionals with more personalized molecular information. We are pleased with the strides being made across the precision-testing industry, energized by the demand we are seeing, and committed to the rigorous work required to move our Company forward.”

Additional information on its line of products will be available on the Company's website at: www.CYductDX.com.
FORWARD-LOOKING STATEMENTS; ADDITIONAL INFORMATION

This press release contains forward-looking statements, including statements regarding Cyduct’s plans, expectations, beliefs, objectives and future performance. Such statements may be identified by words such as “may,” “could,” “will,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “potential” and similar expressions. Forward-looking statements are based on management’s current assumptions, estimates and information and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied. Accordingly, such statements are not guarantees of future performance, and readers should not place undue reliance on them. Additional risks are described in the Company’s Annual Report and other filings with OTC Markets Group, available at www.otcmarkets.com. All forward-looking statements speak only as of the date of this release, and Cyduct undertakes no obligation to update or revise them except as required by law.

CONTACT:
Cyduct Diagnostics, Inc.
Investor Relations +1-888-545-9112
SOURCE: CYduct Diagnostics, Inc.

Elise Grubb
email us here
CYDUCT Diagnostics